AC Immune up on FDA's 'fast-track' tag for Alzheimer's disease therapy

AC Immune SA

27/06/2023 16:59

** Shares of AC Immune SA  ACIU.O  rise 19.2% to $2.36 
    ** Drug developer said FDA has granted fast track
designation for its experimental therapy to treat Alzheimer's
disease
    ** FDA has recently cleared the company to expand the
early-to-mid stage study of the experimental therapy in patients
with Alzheimer's disease   
    ** The fast-track designation facilitates development and
expedites review of drug candidates intended to treat serious
conditions
    ** Including session's gain, stock had risen ~15% YTD 

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))